ACRS Aclaris Therapeutics, Inc.
Price Chart
Executive Summary
Aclaris reported positive full Phase 1a results for ATI-052, an anti-TSLP/IL-4Rα bispecific antibody, showing a 45-day half-life and complete sustained target inhibition, supporting up to every-three-month dosing. The company also selected lichen planus as the lead indication for ATI-2138, an ITK/JAK3 inhibitor, with a Phase 2b basket study expected to start in H2 2026. These updates de-risk the pipeline and expand the addressable market opportunity, though both assets remain in early-stage development with no revenue or near-term catalysts.
Actionable Insight
The strong Phase 1a data for ATI-052 significantly de-risks the asset and supports a best-in-class profile, likely driving near-term upside. Key catalysts to watch: Phase 1b top-line data in asthma/AD (H2 2026) and initiation of Phase 2b programs. The LP indication for ATI-2138 opens a large unaddressed market; monitor enrollment updates. Given the 100% win rate on prior ACRS calls, the market has rewarded pipeline progress—this update reinforces that pattern.
Key Facts
- ATI-052 Phase 1a results show estimated half-life of ~45 days, supporting up to every-three-month dosing.
- Complete and sustained inhibition of TSLP- and IL-4-induced CCL17/TARC through at least week 20 (four months post last dose) in the 480 mg MAD cohort.
- No impact of anti-drug antibodies on PK or PD observed; favorable safety profile with no conjunctivitis.
- Phase 1b trials in asthma and atopic dermatitis are enrolling; top-line results expected H2 2026.
- Phase 2b program for ATI-052 in asthma to initiate in Q4 2026.
- Lichen planus selected as lead indication for ATI-2138; Phase 2b basket study (erosive mucosal, cutaneous, LPP) to start H2 2026.
- Company estimates U.S. market opportunity for an oral LP therapeutic exceeds $1.0B, up to $4.0B.
- No FDA-approved therapies exist for lichen planus; ~40% of patients seek treatment.
- Management to host conference call at 8:30 AM ET today.
Financial Impact
No financial data reported; potential market opportunity for ATI-2138 in LP estimated at $1B-$4B in the U.S.
Risk Factors
- Phase 1b and Phase 2b trials may fail to replicate Phase 1a results in patient populations.
- Competition from approved biologics (e.g., dupilumab, tezepelumab) in asthma/AD could limit ATI-052's commercial potential.
- ATI-2138 faces regulatory and clinical development risks in a disease with no approved therapies.
- No revenue or near-term profitability; reliance on capital markets for funding.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3282383 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Apr 28, 2026
6w ago
|
8-K
| $4.22 $4.58 | ▲ +8.53% | ▲ +3.07% | $4.32 (+2.37%) |
|
Apr 28, 2026
6w ago
|
Press Release
| $4.22 $4.58 | ▲ +8.53% | ▲ +3.07% | $4.32 (+2.37%) |
|
Apr 23, 2026
7w ago
|
DEFA14A
| $4.55 $4.53 | ▼ −0.44% | ▼ −5.07% | $4.32 (−5.05%) |
|
Mar 27, 2026
11w ago
|
Press Release
| $3.52 $4.41 | ▲ +25.28% | ▲ +12.54% | $4.32 (+22.73%) |
|
Mar 20, 2026
12w ago
|
Press Release
| $3.69 $4.25 | ▲ +15.18% | ▲ +5.86% | $4.32 (+17.07%) |
|
Mar 18, 2026
12w ago
|
Press Release
| $3.66 $3.98 | ▲ +8.74% | ▲ +2.70% | $4.32 (+18.03%) |
|
Mar 11, 2026
13w ago
|
8-K
| $3.51 $4.04 | ▲ +15.10% | ▲ +13.12% | $4.32 (+23.08%) |
|
Feb 28, 2026
15w ago
|
Institutional Cluster
| $3.05 $3.49 | ▲ +14.43% | ▲ +22.36% | $4.32 (+41.64%) |
|
Feb 26, 2026
15w ago
|
8-K
| $3.13 $3.52 | ▲ +12.46% | ▲ +18.86% | $4.32 (+38.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access